Konzepte und Ausblick für Patienten über 60 Jahre

Zukunft gestalten - Behandlung von älteren Patienten mit Hodgkin-Lymphom

This is a preview of subscription content, log in to check access.

Abb. 1

© modifiziert nach ghsg.org/therapie

Abb. 2
Abb. 3

© modifiziert nach [10]

Literatur

  1. 1.

    Sjoberg J et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012;26;119(4):990-6

  2. 2.

    Proctor SJ et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005-15

  3. 3.

    Engert A et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23(22):5052-60

  4. 4.

    Enblad G et al. Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol. 1991;2(4):297-302

  5. 5.

    Wongso D et al. Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group. J Clin Oncol. 2013;31(22):2819-24

  6. 6.

    Evens AM et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3):692-5

  7. 7.

    Böll B et al. ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials. J Clin Oncol. 2013;31(12):1522-9

  8. 8.

    Borchmann S et al. Hodgkin lymphoma in elderly patients. Curr Opin Oncol. 2018;30(5):308-16

  9. 9.

    Engert A. Treatment of elderly Hodgkin lymphoma patients. Hematol Oncol 2019;37(Suppl 1):92-4

  10. 10.

    Böll B et al. Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group. J Clin Oncol. 2013;31(35):4431-7

  11. 11.

    Puig N et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplant. 2011;46(10):1339-44

  12. 12.

    Santoro A et al. Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study. J Clin Oncol. 2000;18(13):2615-9

  13. 13.

    Younes A et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-9

  14. 14.

    Forero-Torres A et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798-804

  15. 15.

    Connors JM et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018;378(4):331-44

  16. 16.

    Evens AM et al. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol. 2018;36(30):3015-22

  17. 17.

    Böll B et al. B-CAP (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and predniso(lo)Ne) in older patients with advanced-stage hodgkin lymphoma: results of a phase II intergroup trial By the German Hodgkin study group (GHSG) and the Nordic Lymphoma group (NLG). Oncol Res Treat. 2019;42(suppl 4):Abstr V609

  18. 18.

    Armand P et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016;34(31):3733-9

  19. 19.

    Kasamon YL et al. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Oncologist. 2017;22(5):585-91

  20. 20.

    Armand P et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428-39

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Priv.-Doz. Dr. med. Boris Böll.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Böll, B., Momotow, J. Zukunft gestalten - Behandlung von älteren Patienten mit Hodgkin-Lymphom. Im Fokus Onkologie 23, 15–18 (2020). https://doi.org/10.1007/s15015-020-2423-1

Download citation